Eagle Asset Management Inc. Trims Stock Position in Haemonetics Co. (NYSE:HAE)

Eagle Asset Management Inc. cut its stake in Haemonetics Co. (NYSE:HAE) by 54.1% in the third quarter, Holdings Channel.com reports. The fund owned 100,565 shares of the medical instruments supplier’s stock after selling 118,636 shares during the quarter. Eagle Asset Management Inc.’s holdings in Haemonetics were worth $8,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of HAE. Quarry LP acquired a new stake in shares of Haemonetics during the second quarter worth about $39,000. Daiwa Securities Group Inc. purchased a new position in Haemonetics during the second quarter worth about $82,000. Canada Pension Plan Investment Board purchased a new position in Haemonetics during the second quarter worth about $83,000. Nisa Investment Advisors LLC raised its holdings in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Haemonetics during the second quarter worth about $140,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Trading Up 0.1 %

NYSE HAE opened at $85.55 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The company has a 50-day simple moving average of $78.75 and a 200-day simple moving average of $82.32. The firm has a market capitalization of $4.30 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 1.33 and a beta of 0.32. Haemonetics Co. has a one year low of $70.25 and a one year high of $97.97.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. During the same period in the previous year, the firm earned $0.99 EPS. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. On average, equities analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on HAE shares. BTIG Research started coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. Citigroup dropped their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. CL King began coverage on shares of Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price for the company. Barrington Research reiterated an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.